While the world obsesses over AI models and software, a quiet revolution is happening in the lab. RENOVO is betting that the future of biotech isn't just code—it's the physical devices that manipulate biology itself. They aren't selling software; they're selling the hardware that makes the science possible.

"RENOVO ignores the venture-backed hype cycle to build tangible tools for working scientists."

The most telling data point is the '0' monthly web visits. In an era of SEO obsession, RENOVO operates almost entirely offline or through direct B2B relationships. This suggests a sales model driven by word-of-mouth, academic conferences, and direct engineering consultation rather than inbound content marketing. It’s a classic deep-tech play: build a superior product, and the customers (often researchers) find you through industry networks.

• Vertical Focus: Specialized in bioprinters and syringe pumps—high-precision niches.
• Bootstrapped Efficiency: $2.3M revenue without disclosed funding indicates sustainable growth.
• Direct-to-Scientist: Bypassing distribution channels to offer better pricing and direct support.